Truqap is usually a kinase inhibitor that works by blocking pathways that assist the most cancers cells survive and develop, so minimizes cancer development. Truqap is from a category of medicines identified as an AKT inhibitor. Truqap acquired FDA acceptance on November 17, 2023, following positive